A new analysis of PROSPER, presented at AUA 2018, suggests enzalutamide plus ADT may be superior to ADT alone in nonmetastatic CRPC.
A study led by Dr. Jun Mao of MSKCC found CBT and acupuncture each yielded clinically meaningful and durable sleep-related QOL improvements.
Recurrence risk was greater in sarcopenic patients, and greater alpha-fetoprotein and microvascular invasion were independent risk factors.
Certain genetic alterations associated with anaplastic transformation in thyroid cancer made patients sensitive to the multikinase inhibitor lenvatinib.
A pooled retrospective analysis of nearly 5,000 mRCC patients in phase II and III trials showed PFS among NSAIDs users was half that of NSAIDs nonusers.
Activating CD40 is “a key to initiating a T-cell response to tumors,” says Dr. Robert Vonderheide, MD, director of U Penn’s Abramson Cancer Center.
A retrospective study of ICIs by French investigators found manageable toxicity in patients over age 70, and survival outcomes comparable to younger patients.
T-ALL may be treatable by targeting signaling pathways affected by STIL-TAL1 fusion, according to a team from The Institute of Cancer Research, London, UK.
A Cleveland Clinic team found patients with false-positive results subsequently become more involved in cancer screening programs.
“The core message is that DLBCL can no longer be viewed as a single disease,” explained senior author Dr. Louis M. Staudt, Director of NCI’s Center for Cancer Genomics.